Last reviewed · How we verify
NCT06751667: LIBERO
Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer
NA trial testing Urinary biomarkers in Bladder (Urothelial, Transitional Cell) Cancer in 50 participants. Not yet recruiting.
1 January 2027
Quick facts
| Lead sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 50 |
| Start date | 1 January 2025 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2032 |
Drugs / interventions tested
- Urinary biomarkers
Conditions studied
- Bladder (Urothelial, Transitional Cell) Cancer — all drugs for Bladder (Urothelial, Transitional Cell) Cancer →
- Bladder Cancer — all drugs for Bladder Cancer →
- Bladder Tumors — all drugs for Bladder Tumors →
- Bladder Cancer Recurrence — all drugs for Bladder Cancer Recurrence →
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full company profile →
Who can join
18 and older, any sex, with Bladder (Urothelial, Transitional Cell) Cancer or Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Main objectives: Qualitative and quantitative monitoring of recurrences in patients with a previous diagnosis of high-grade bladder cancer at high risk of persistence/recurrence. Endpoints: Presence or absence of mRNA in urine with a dichotomous result; concordance between Xpert BM and histopathological examination Clinical relevance: reduces by half the number of (invasive) cystoscopies during follow-up. The non-invasive nature of the test could improve patient compliance with follow-up. Interventional study because it would reduce by half the number of cystoscopies during follow-up of bladder cancer which is considered the gold standard in the follow-up of this tumor. However, these markers are already CE validated and described in the European guidelines and for this reason the risk would be low.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06751667
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Urinary biomarkers
Trials testing the same drug.
- NCT06606522 — A Clinical Diagnostic System for Intrinsic Acute Kidney Disease · completed
Other recruiting trials for Bladder (Urothelial, Transitional Cell) Cancer
Currently open trials in the same condition.
- NCT07589413 — Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT · recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT06787053 — Selecting Hypoxic Tumours for Treatment Modification · recruiting
- NCT06696742 — PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma · Phase 2 · recruiting
Other Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials
Trials by the same sponsor.
- NCT06799624 — Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr · not yet recruiting
- NCT07253402 — Microbiota-guided Radiotherapy for Head and Neck Cancer · recruiting
- NCT06938724 — Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT06999824 — Revisiting the Concept of Nerve Sparing Radical Hysterectomy · not yet recruiting
- NCT06986486 — Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06751667 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Last refreshed: 30 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06751667.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing